Economic burden of growth hormone deficiency among adults who are at risk for and who have confirmed growth hormone deficiency using US real-world data
All-cause healthcare costs were higher among individuals with confirmed AGHD or at risk for AGHD than among adults without GHD. After excluding the cost of GH therapy, lower adjusted AGHD-related costs were associated with both a confirmed AGHD diagnosis and receipt of GH treatment.
Authors
- Andrew R. Hoffman (ORCID: https://orcid.org/0000-0002-0145-1917)
- Jennifer Cheng (ORCID: https://orcid.org/0000-0001-8458-619X)
- Isabelle Winer (ORCID: https://orcid.org/0000-0002-7294-8162)
- Allison Komirenko (ORCID: https://orcid.org/0000-0001-8844-2804)
- Janna Manjelievskaia (ORCID: https://orcid.org/0000-0002-8293-512X)
- Jessamine Winer‐Jones (ORCID: https://orcid.org/0000-0002-6412-4139)
- Alden Smith (ORCID: https://orcid.org/0000-0003-1582-534X)
- Machaon Bonafede (ORCID: https://orcid.org/0000-0001-6330-6718)
- Subhara Raveendran (ORCID: https://orcid.org/0000-0003-0151-6298)
- Paul Miner
Institutions
- Ascendis Pharma (Denmark) (DK)
- Stanford Medicine (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1080/13696998.2025.2548741
- Citations
- 1
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 1.29